Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Activated natural killer cell therapy - NantKwest

Drug Profile

Activated natural killer cell therapy - NantKwest

Alternative Names: aNK cells - NantKwest; CST-101; Neukoplast; NK-92 cells; ZRx-101

Latest Information Update: 08 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ZelleRx
  • Developer Johann Wolfgang Goethe-Universitat Frankfurt am Main; NantCell; NantKwest; Rush University; University Health Network; University of Pittsburgh Medical Center; ZelleRx
  • Class Anti-infectives; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Merkel cell carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Merkel cell carcinoma
  • Phase I/II Pancreatic cancer
  • Preclinical Infections; Liver cancer
  • No development reported Acute myeloid leukaemia; Haematological malignancies; Malignant melanoma; Renal cancer; Solid tumours
  • Discontinued Graft-versus-host disease; Leukaemia; Multiple myeloma; Sarcoma

Most Recent Events

  • 27 Dec 2017 NantKwest initiates enrolment in the phase I/II QUILT3-070 trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (NCT03387098)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in USA (Parenteral, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Haematological-malignancies(Second-line therapy or greater) in Canada (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top